LP
NRIX icon

Longaeva Partners’s Nurix Therapeutics NRIX Stock Holding History

Longaeva Partners’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$23.1M Buy
1,490,202
+562,473
+61% +$9.33M 0.86% 30
2025
Q4 		$17.6M Buy
+927,729
New +$13.3M 1.48% 16

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Longaeva Partners's NRIX Position: Q1 2026 in Review

Longaeva Partners increased its Nurix Therapeutics (NRIX) stake by 61% in Q1 2026, buying an estimated $9.33M and bringing the position to 1,490,202 shares worth $23.1M. The position accounts for 0.86% of the portfolio, ranked #30.

Longaeva Partners first reported a position in NRIX in Q4 2025 and has held it in 2 quarters since. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Longaeva Partners held 1,490,202 shares of Nurix Therapeutics worth $23.1M as of Q1 2026.
  • Longaeva Partners bought 562,473 Nurix Therapeutics shares in Q1 2026, an estimated $9.33M.
  • Nurix Therapeutics made up 0.86% of Longaeva Partners's portfolio in Q1 2026, its #30 holding.
  • Longaeva Partners first reported a position in Nurix Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Longaeva Partners's 13F filing for Q1 2026, filed 15 May 2026.